As our appreciation of the fundamental role of dysregulated NF-κB signalling in the pathogenesis of inflammatory disease and cancer continues to grow so the resolve of the pharmaceutical industry to pharmacologically target NF-κB pathway components strengthens. The gene discussed is NFKB1; the disease is cancer.